MS Vaccine

March 2009
PN;Mar2009, Vol. 63 Issue 3, p14
Trade Publication
The focuses on ATX-MS-1467, a peptide therapeutic vaccine for multiple sclerosis (MS) from Apitope International NV. It states that Apitope and the Fast Forward LLC, which is a subsidiary company of National Multiple Sclerosis Society, have formed a partnership to support Apitope's proof-of-principle clinical trial of the MS vaccine. It discusses the progress of the clinical trials for MS vaccine, which indicated that the drug is safe and well tolerated and has promising evidence of efficacy.


Related Articles

  • Fast Forward supports novel therapy for MS.  // Momentum (19403410);Spring2009, Vol. 2 Issue 2, p26 

    This article reports that Fast Forward LLC, which was launched by the National Multiple Sclerosis (MS) Society in 2008 to increase the number of MS drugs in the pipeline, has announced its first award, $1 million to a Belgian biopharmaceutical company for a therapy that holds promise for people...

  • OTHER NEWS TO NOTE.  // BioWorld International;12/31/2008, Vol. 13 Issue 53, p2 

    This section offers news briefs on the biotechnology industry. Apitope International NV and Fast Forward LLC partnered to support Apitope's trial of ATX-MS-1467, a peptide therapeutic vaccine designed to target abnormal immune response in multiple sclerosis. Celgene International Sarl has...

  • Fast Forward. Durand, Marcella // Momentum (19403410);Summer2009, Vol. 2 Issue 3, p27 

    The article focuses on the efforts of Fast Forward LLC, a subsidiary of the National Multiple Sclerosis Society in the U.S., to help biotechnology companies by funding their clinical trials. Timothy Coetzee of Fast Forward cited the presence of a funding gap between the early stages of...

  • EMD Serono, Inc. and FAST FORWARD, LLC Announce Recipients of Funding for Multiple Sclerosis Research.  // Biomedical Market Newsletter;7/5/2011, p168 

    The article reports on the announcement by Fast Forward LLC and EMD Serono Inc. regarding the second batch of recipients of its funding program for multiple sclerosis (MS) research. It states that the funding totaled to over one million dollars and will be allocated from the two funds of Fast...

  • Clinic Roundup.  // BioWorld Today;11/27/2012, Vol. 23 Issue 229, p8 

    This section offers news briefs on clinical trials. A clinical trial was initiated by Accera Inc. that examines the effect of AC-1204 in patients with Alzheimer's disease. Patient recruitment was completed by Apitope International NV for a Phase I trial of ATX-MS-1467 in multiple sclerosis....

  • Merck reports encouraging data from Phase III multiple sclerosis trial.  // PharmaWatch: Biotechnology;Aug2009, Vol. 8 Issue 8, p8 

    The article reports on the positive results on the Phase III multiple sclerosis trial conducted by Merck Serono, a division of Merck KGaA, in the U.S. The post-hoc analyses of Merck on the two-year placebo-controlled Clarity Phase III trial using cladribine tablets has recorded significant...

  • Towards a European Network for Multiple Sclerosis Trials (ENMST). Kappos, L; Polman, C; Thompson, AJ; Duda, P; Clanet, M; Comi, G; Hartung, HP; Montalban, X // Multiple Sclerosis (13524585);Dec2003, Vol. 9 Issue 6, p627 

    Quality standards for clinical studies in the field of multiple sclerosis (MS) have improved significantly, to the great benefit of patients. This development has been accompanied by soaring costs and ever increasing complexity, with industry-independent trials having become virtually...

  • Pipeline.  // Pharmaceutical Representative;Apr2010, Vol. 40 Issue 4, p10 

    The article offers information on drug testing studies. It says that Clabridine treatment for multiple sclerosis lowers annualized rate of relapse than in the placebo group with 0.14 and 0.15 vs, 0.33. Phase III study of SUN 1064 or sunitinib malate in advanced breast cancer did not show...

  • T-cell vaccine for MS. Bird, Lucy // Nature Reviews Immunology;Apr2006, Vol. 6 Issue 4, p258 

    Reports on a large-scale trial to test the efficacy of a personalized T-cell vaccine in patients with multiple sclerosis. Explanation that the large-scale test follows a promising results of a multiple sclerosis vaccine trial in a small group of patients; Information on the vaccine developed by...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics